A functional and regulatory network associated with PIP expression in human breast cancer

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Debily, Marie Anne ^a,b,c   El Marhomy, Sandrine ^a   Boulanger, Virginie ^a   Eveno, Eric ^a   Mariage Samson, Régine ^a   Camarca, Alessandra ^d   Auffray, Charles ^a   Piatier Tonneau, Dominique ^a   Imbeaud, Sandrine ^a,e,f  

^a SORBONNE UNIVERSITÉ   (France)

^b DIF   (France)

^c UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^d CNR   (Italy)

^e CENTRE DE GÉNÉTIQUE MOLÉCULAIRE   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ONCOPROTEIN; PROLACTIN INDUCIBLE PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; GLYCOPROTEIN; PIP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROMOTER REGION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CLUSTER ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENETICS; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GLYCOPROTEINS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; STAT5 TRANSCRIPTION FACTOR;

EID: 61949109023     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004696     Document Type: Article

References (116)

1. McPherson K, Steel CM, Dixon JM (1994) ABC of breast diseases. Breast cancer epidemiology, risk factors and genetics. BMJ 309: 1003-1006.
2. Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, et al. (1999) Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 80: 419-426.
3. Brenner AJ, Aldaz CM (1997) The genetics of sporadic breast cancer. Prog Clin Biol Res 396: 63-82.
4. Wells CA, McGregor IL, Makunura CN, Yeomans P, Davies JD (1995) Apocrine adenosis: a precursor of aggressive breast cancer? J Clin Pathol 48: 737-742.
5. Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, et al. (1989) Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 20: 281-287.
6. Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, et al. (2008) Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol 39: 666-671.
7. Fiel MI, Cernaianu G, Burstein DE, Batheja N (1996) Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol 40: 637-641.
8. Zagorianakou P, Zagorianakou N, Stefanou D, Makrydimas G, Agnantis NJ (2006) The enigmatic nature of apocrine breast lesions. Virchows Arch 448: 525-531.
9. Perry A, Parisi JE, Kurtin PJ (1997) Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Hum Pathol 28: 938-943.
10. Akasofu M, Kawahara E, Kurumaya H, Nakanishi I (1993) Immunohistochemical detection of breast specific antigens and cytokeratins in metastatic breast carcinoma in the liver. Acta Pathol Jpn 43: 736-744.
11. Monteagudo C, Merino MJ, LaPorte N, Neumann RD (1991) Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary. Hum Pathol 22: 368-372.
12. Park SY, Kim BH, Kim JH, Lee S, Kang GH (2007) Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 131: 1561-1567.
13. Murphy LC, Lee-Wing M, Goldenberg GJ, Shiu RPC (1987) Expression of the gene encoding a prolactin-inducible protein in human breast cancers in vivo: a correlation with steroid receptor status. Cancer Res 47: 4160-4164.
14. Clark JW, Snell L, Shiu RP, Orr FW, Maitre N, et al. (1999) The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br J Cancer 81: 1002-1008.
15. Haagensen JDE, Mazoujian G (1986) Biochemistry and immunochemistry of gross cystic disease fluid proteins of the breast. In: Haagensen CD, ed. Diseases of the Breast. 3rd ed. Philadelphia: Saunders, W.B. pp 474-500.
16. Autiero M, Abrescia P, Guardiola J (1991) Interaction of seminal plasma proteins with cell surface antigens: presence of a CD4-binding glycoprotein in human seminal plasma. Exp Cell Res 197: 268-271.
17. Autiero M, Cammarota G, Friedlein A, Zulauf M, Chiappetta G, et al. (1995) A 17 kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells. Eur J Immunol 25: 1461-1464.
18. Basmaciogullari S, Autiero M, Culerrier R, Mani JC, Gaubin M, et al. (2000) Mapping the interaction site between CD4 and gp17, a glycoprotein secreted from seminal vesicles and breast carcinomas. Biochemistry 39: 5332-5340.
19. Gaubin M, Autiero M, Basmaciogullari S, Métivier D, Mishal Z, et al. (1999 Potent inhibition of CD4/TCR-mediated T cell apoptosis by a CD4-binding glycoprotein secreted from breast tumor and seminal vesicle cells. J Immunol 162: 2631-2638.
20. Caputo E, Manco G, Mandrich L, Guardiola J (2000) A novel aspartyl proteinase from apocrine epithelia and breast tumors. J Biol Chem 275: 7935-7941.
21. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
22. Autiero M, Culerrier R, Bouchier C, Basmaciogullari S, Gaubin M, et al. (1999) Abnormal restriction pattern of PIPgene associated with human primary prostate cancers. DNA Cell Biol 18: 481-487.
23. Autiero M, Camarca A, Ciullo M, Debily MA, El Marhomy S, et al. (2002) Intragenic amplification and formation of extrachromosomal small circular DNA molecules from the PIP gene on chromosome 7 in primary breast carcinomas. Int J Cancer 99: 370-377.
24. Ciullo M, Debily MA, Rozier L, Autiero M, Billault A, et al. (2002) Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I. Hum Mol Genet 11: 2887-2894.
25. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, et al. (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544.
26. Loos S, Schulz KD, Hackenberg R (1999) Regulation of GCDFP-15 expression in human mammary cancer cells. Int J Mol Med 4: 135-140.
27. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
28. Simard J, Hatton AC, Labrie C, Dauvois S, Zhao HF, et al. (1989) Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. Mol Endocrinol 3: 694-702.
29. ([http://genome-www5.stanford.edu/cgibin/source/sourceSearch]) The SOURCE browser.
30. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
31. Chao DT, Korsmeyer SJ (1998) BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419.
32. Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA (1995) Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res 55: 3250-3253.
33. Campbell I, Magliocco A, Moyana T, Zheng C, Xiang J (2000) Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer Gene Ther 7: 1270-1278.
34. Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, et al. (1997) Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J Cell Biol 136: 935-944.
35. Tajeddine N, Gala JL, Louis M, Van Schoor M, Tombal B, et al. (2005) Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 65: 7348-7355.
36. Fox BP, Kandpal RP (2004) Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318: 882-892.
37. Rhee K, Bresnahan W, Hirai A, Hirai M, Thompson EA (1995) c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation. Cancer Res 55: 4188-4195.
38. Duan J, Chen Z, Liu P, Zhang Z, Tong T (2004) Wild-type p16INK4a suppresses cell growth, telomerase activity and DNA repair in human breast cancer MCF-7 cells. Int J Oncol 24: 1597-1605.
39. Parri M, Buricchi F, Taddei ML, Giannoni E, Raugei G, et al. (2005) EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J Biol Chem 280: 34008-34018.
40. Cho DI, Oak MH, Yang HJ, Choi HK, Janssen GM, et al. (2003) Direct and biochemical interaction between dopamine D3 receptor and elongation factor-1Bbetagamma. Life Sci 73: 2991-3004.
41. Le Sourd F, Boulben S, Le Bouffant R, Cormier P, Morales J, et al. (2006) eEF1B: At the dawn of the 21st century. Biochim Biophys Acta 1759: 13-31.
42. Lim JH, Park JW, Chun YS (2006) Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res 66: 10677-10682.
43. Agbaria R, Kelley JA, Jackman J, Viola JJ, Ram Z, et al. (1997) Antiproliferative effects of cyclopentenyl cytosine (NSC 375575) in human glioblastoma cells. Oncol Res 9: 111-118.
44. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, Csiszar K, Fong KS, et al. (2005) A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. Embo J 24: 3446-3458.
45. Riegel AT, Wellstein A (1994) The potential role of the heparin-binding growth factor pleiotrophin in breast cancer. Breast Cancer Res Treat 31: 309-314.
46. Li T, Sparano JA (2003) Inhibiting Ras signaling in the therapy of breast cancer. Clin Breast Cancer 3: 405-416; discussion 417-420.
47. Garbay C, Liu WQ, Vidal M, Roques BP (2000) Inhibitors of Ras signal transduction as antitumor agents. Biochem Pharmacol 60: 1165-1169.
48. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, et al. (2006) The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 8: R28.
49. Huang W, Tan D, Wang X, Han S, Tan J, et al. (2006) Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1. Biochem Biophys Res Commun 339: 165-171.
50. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, et al. (2003) Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310: 529-536.
51. Bowden ET, Stoica GE, Wellstein A (2002) Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 277: 35862-35868.
52. Kim K, Cai J, Shuja S, Kuo T, Murnane MJ (1998) Presence of activated ras correlates with increased cysteine proteinase activities in human colorectal carcinomas. Int J Cancer 79: 324-333.
53. Kudoh M, Knee DA, Takayama S, Reed JC (2002) Bag1 proteins regulate growth and survival of ZR-75-1 human breast cancer cells. Cancer Res 62: 1904-1909.
54. Tobin DJ, Foitzik K, Reinheckel T, Mecklenburg L, Botchkarev VA, et al. (2002) The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am J Pathol 160: 1807-1821.
55. Qin W, Hu J, Guo M, Xu J, Li J, et al. (2003) BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis. Biochem Biophys Res Commun 308: 379-385.
56. Yang X, Wei LL, Tang C, Slack R, Mueller S, et al. (2001) Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res 61: 5284-5288.
57. Liu WM, Zhang XA (2006) KAI1/CD82, a tumor metastasis suppressor. Cancer Lett 240: 183-194.
58. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, et al. (2002) Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50: 392-401.
59. Wang CH, Chang HC, Hung WC (2006) p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription. J Cell Physiol 208: 246-252.
60. Miao H, Burnett E, Kinch M, Simon E, Wang B (2000) Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2: 62-69.
61. Mogi S, Dang D, Van Waes C, Ellis D, Atakilit A, et al. (2005) The expression of integrin alpha(v)beta6 promotes the epithelial cell morphology and suppresses invasive behavior in transformed oral keratinocytes. Anticancer Res 25: 751-755.
62. Glading A, Koziol JA, Krueger J, Ginsberg MH (2007) PEA-15 Inhibits Tumor Cell Invasion by Binding to Extracellular Signal-Regulated Kinase 1/2. Cancer Res 67: 1536-1544.
63. Mylona E, Nomikos A, Magkou C, Kamberou M, Papassideri I, et al. (2007) The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology 50: 338-347.
64. Kim HJ, Park CI, Park BW, Lee HD, Jung WH (2006) Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 47: 333-342.
65. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, et al. (2005) Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26: 943-950.
66. Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, et al. (2006) Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66: 7176-7184.
67. Sandberg R, Ernberg I (2005) The molecular portrait of in vitro growth by meta-analysis of gene-expression profiles. Genome Biol 6: R65.
68. Lyzak JS, Yaremko ML, Recant W, Baunoch DA, Joseph L (1997) Role of CD44 in nonpalpable T1a and T1b breast cancer. Hum Pathol 28: 772-778.
69. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S (1993) Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 143: 867-874.
70. Yasuda M, Tanaka Y, Fujii K, Yasumoto K (2001) CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. Int Immunol 13: 1309-1319.
71. Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, et al. (2000) Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 28: 31-39.
72. Barabasi AL, Oltvai ZN (2004) Network biology: understanding the cell's functional organization. Nat Rev Genet 5: 101-113.
73. Benson M, Breitling R (2006) Network theory to understand microarray studies of complex diseases. Curr Mol Med 6: 695-701.
74. Chuang HY, Lee E, Liu YT, Lee D, Ideker T (2007) Network-based classification of breast cancer metastasis. Mol Syst Biol 3: 140.
75. Nagarajan R, Svaren J, Le N, Araki T, Watson M, et al. (2001) EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 30: 355-368.
76. ([http://www.genomatix.de/products/ElDorado/index.html]) ElDoradoe/ Gene2promotor system.
77. Kloth MT, Catling AD, Silva CM (2002) Novel activation of STAT5b in response to epidermal growth factor. J Biol Chem 277: 8693-8701.
78. Cull VS, Tilbrook PA, Bartlett EJ, Brekalo NL, James CM (2003) Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 101: 2727-2735.
79. Leonard WJ, O'Shea JJ (1998) Jaks and STATs: biological implications. Annu Rev Immunol 16: 293-322.
80. Meyer AN, Gastwirt RF, Schlaepfer DD, Donoghue DJ (2004) The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation. J Biol Chem 279: 28450-28457.
81. Hwa V, Little B, Kofoed EM, Rosenfeld RG (2004) Transcriptional regulation of insulin-like growth factor-I by interferon-gamma requires STAT-5b. J Biol Chem 279: 2728-2736.
82. Brizzi MF, Dentelli P, Rosso A, Calvi C, Gambino R, et al. (2004) RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. Faseb J 18: 1249-1251.
83. Banno T, Gazel A, Blumenberg M (2004) Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 279: 32633-32642.
84. Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA (2003) Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene 22: 1955-1964.
85. Humphreys RC, Hennighausen L (1999) Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 10: 685-694.
86. Iavnilovitch E, Groner B, Barash I (2002) Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 1: 32-47.
87. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, et al. (2002) Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 11: 863-872.
88. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, et al. (2004) Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22: 2053-2060.
89. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, et al. (2005) Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24: 746-760.
90. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, et al. (2006) Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 66: 1824-1832.
91. Barash I (2006) Stat5 in the mammary gland: controlling normal development and cancer. J Cell Physiol 209: 305-313.
92. Gutzman JH, Rugowski DE, Nikolai SE, Schuler LA (2007) Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context. Oncogene.
93. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, et al. (2004) Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665-671.
94. Carsol JL, Gingras S, Simard J (2002) Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. Mol Endocrinol 16: 1696-1710.
95. Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, et al. (2007) Coexpression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol 22: 1221-1230.
96. Vandewalle B, Collyn d'Hooghe M, Savary JB, Vilain MO, Peyrat JP, et al. (1987) Establishment and characterization of a new cell line (VHB-1) derived from a primary breast carcinoma. J Cancer Res Clin Oncol 113: 550-558.
97. Imbeaud S, Graudens E, Boulanger V, Barlet X, Zaborski P, et al. (2005) Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res 33: e56.
98. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3.
99. Maniatis T, Fritsch EF, Sambrook J (1982) Molecular cloning: a laboratory Manual. New-York: Cold Spring Harbor Laboratory Press.
100. Autiero M, Bouchier C, Basmaciogullari S, Zaborski P, El Marhomy S, et al. (1997) Isolation from a human seminal vesicle library of the cDNA for gp17, a CD4 binding factor. Immunogenetics 46: 345-348.
101. Alonso S, Minty A, Bourlet Y, Buckingham M (1986) Comparison of three actin-coding sequences in the mouse; evolutionary relationships between the actin genes of warm-blooded vertebrates. J Mol Evol 23: 11-22.
102. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, et al. (2006) Deciphering cellular states of innate tumor drug responses. Genome Biol 7: R19.
103. ([http://fre2571.vjf.cnrs.fr]) The Genexpress - Array s/IMAGE web site.
104. ([http://image.llnl.gov/]) The I.M.A.G.E. Consortium resources.
105. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, et al. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-371.
106. ([http://www.ncbi.nlm.nih.gov/geo/]) Gene Expression Omnibus GEO.
107. Hwang D, Schmitt WA, Stephanopoulos G (2002) Determination of minimum sample size and discriminatory expression patterns in microarray data. Bioinformatics 18: 1184-1193.
108. (http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/) GPower3 program.
109. Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
110. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
111. Rhodes DR, Miller JC, Haab BB, Furge KA (2002) CIT: identification of differentially expressed clusters of genes from microarray data. Bioinformatics 18: 205-206.
112. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser 57: 289-300.
113. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
114. ([http://www.appliedbiosystems.com]) Applied Biosystems.
115. ([https://www.ingenuity.com]) Ingenuity® Systems.
116. ([http://www.genomatix.de/products/GEMSLauncher/index.html]) Geno-matix GEMS Launcher.